Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль капецитабина и эрибулина в лечении метастатического HER2-негативного распространенного рака молочной железы
Роль капецитабина и эрибулина в лечении метастатического HER2-негативного распространенного рака молочной железы
Колядина И.В., Поддубная И.В. Роль капецитабина и эрибулина в лечении метастатического HER2-негативного распространенного рака молочной железы. Современная Онкология. 2018; 20 (3): 26–29. DOI: 10.26442/1815-1434_2018.3.26-29
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре проанализирована роль капецитабина и эрибулина в терапии HER2-негативного распространенного рака молочной железы (РМЖ) у пациенток, предлеченных антрациклинами и таксанами. Описаны механизм противоопухолевого действия капецитабина и эрибулина, эффективность препаратов при различных биологических подтипах заболевания, а также проанализирована безопасность терапии данным цитостатиками у больных РМЖ. Представлены результаты сравнительного анализа эффективности и безопасности монотерапии эрибулином по сравнению с терапией капецитабином в качестве 2-й линии лечения распространенного HER2-негативного РМЖ.
Ключевые слова: HER2-негативный метастатический рак молочной железы, химиотерапия капецитабином, химиотерапия эрибулином, эффективность химиотерапии при антрациклин- и таксан-резистентном раке молочной железы, общая выживаемость, профиль безопасности эрибулина и капецитабина.
Key words: HER2-negative metastatic breast cancer, capecitabine chemotherapy, eribulin chemotherapy, chemotherapy efficacy for anthracycline and taxane-resistant breast cancer, overall survival, safety profile of eribulin and capecitabine.
Ключевые слова: HER2-негативный метастатический рак молочной железы, химиотерапия капецитабином, химиотерапия эрибулином, эффективность химиотерапии при антрациклин- и таксан-резистентном раке молочной железы, общая выживаемость, профиль безопасности эрибулина и капецитабина.
________________________________________________
Key words: HER2-negative metastatic breast cancer, capecitabine chemotherapy, eribulin chemotherapy, chemotherapy efficacy for anthracycline and taxane-resistant breast cancer, overall survival, safety profile of eribulin and capecitabine.
Полный текст
Список литературы
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin 2014; 64 (1): 9–29.
2. Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная онкология. 2014; 16 (4): 10–20. / Kolyadina I.V., Poddubnaya I.V. Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials). Journal of Modern Oncology. 2014; 16 (4): 10–20. [in Russian]
3. Jacquet E, Lardy-Cléaud A, Pistilli B et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 2018; 95: 93–101. DOI: 10.1016/j.ejca.2018.03.013
4. Gobbini E, Ezzalfani M, Dieras V et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 2018; 96:17–24.
5. Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18 (2): 123–33.
6. Ngan RKC. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. Ann Transl Med 2018; 6 (14): 284. DOI: 10.21037/atm.2018.06.11
7. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw 2018;16 (5S): 605–10. DOI: 10.6004/jnccn.2018.0043
8. Hayashida T, Jinno H, Mori K et al. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial. BMC Cancer 2018; 18 (1): 701. DOI: 10.1186/s12885-018-4628-7
9. Iizumi S, Shimomura A, Shimoi T et al. Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. Cancer Chemother Pharmacol 2018. DOI: 10.1007/s00280-018-3617-5
10. Montagna E, Bagnardi V, Cancello G et al. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel) 2018; 13 (3): 177–81. DOI: 10.1159/000487630
11. Egger SJ, Willson ML, Morgan J. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017; 23 (6): CD003374. DOI: 10.1002/14651858.CD003374.pub4
12. Stein J, Mann J. Specialty pharmacy services for patients receiving oral medications for solid tumors. Am J Health Syst Pharm 2016; 73 (11): 775–96. DOI: 10.2146/ajhp150863
13. Поддубная И.В., Колядина И.В. Эффективная терапия рака молочной железы препаратами для перорального приема. Современная онкология. 2009. 11 (3): 36–8. / Poddubnaia I.V., Koliadina I.V. Effektivnaia terapiia raka molochn oi zhelezy preparatami dlia peroral'nogo priema. Journal of Modern Oncology. 2009. 11 (3): 36–8. [in Russian]
14. Li YS, Yang Q, Qi M et al. Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study. Mol Clin Oncol 2017; 7 (4): 661–6. DOI: 10.3892/mco.2017.1351
15. Поддубная И.В., Колядина И.В., Макаренко Н.П. Сборник клинических случаев длительного применения препарата кселода. Под ред. И.В.Поддубной. М., 2012. / Poddubnaya I.V., Koliadyna I.V., Makarenko N.P. Sbornik klinicheskikh sluchaev dlitel'nogo primeneniia preparata kseloda. Pod red. I.V.Poddubnoi. M., 2012. [in Russian]
16. Колядина И.В., Поддубная И.В. Капецитабин в адъювантной терапии рака молочной железы. Современная онкология. 2010; 12 (3): 23–7. / Kolyadina I.V., Poddubnaya I.V. Kapetsitabin v ad"iuvantnoi terapii raka molochnoi zhelezy. Journal of Modern Oncology. 2010; 12 (3): 23–7. [in Russian]
17. Инструкция по препарату Капецитабин. https: //www. rlsnet.ru/mnn_index_id_2696.htm / Instruktsiia po preparatu Kapetsitabin. https://www.rlsnet.ru/mnn_index_id_2696.htm [in Russian]
18. Hong JY, Park YH, Choi MK. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clin Breast Cancer 2015; 15 (5): e287–92. DOI: 10.1016/j.clbc.2015.04.004
19. Gilabert M, Bertucci F, Esterni B et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res 2011; 31 (3): 1079–86.
20. Park IH, Im SA, Jung KH et al. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Res Treat 2018. DOI: 10.4143/crt.2017.562. Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
21. Babacan T et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori 2015; 101 (4): 418–23.
22. McBride A, Butler SK. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. Am J Health Syst Pharm 2012; 69 (9): 745–55. DOI: 10.2146/ajhp110237
23. Aseyev O, Ribeiro JM, Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 2016; 17 (4): 589–600. DOI: 10.1517/14656566.2016. 1146683
24. O'Shaughnessy J, McIntyre K, Schwartzberg L et al. Impact of prior antОРacycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. Springerplus 2015; 4: 532. DOI: 10.1186/s40064-015-1322-y
25. Электронный ресурс. http://clincancerres.aacrjournals.org/content/17/21/6615 / Elektronnyi resurs. http://clincancerres.aacrjournals.org/content/17/21/6615 [in Russian]
26. Pivot X. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27 (8): 1525–31. DOI:10.1093/annonc/mdw203
27. Pivot X, Im SA, Guo M et al. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018; 25 (3): 370–4. DOI: 10.1007/s12282-017-0826-4
2. Kolyadina I.V., Poddubnaya I.V. Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials). Journal of Modern Oncology. 2014; 16 (4): 10–20. [in Russian]
3. Jacquet E, Lardy-Cléaud A, Pistilli B et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 2018; 95: 93–101. DOI: 10.1016/j.ejca.2018.03.013
4. Gobbini E, Ezzalfani M, Dieras V et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 2018; 96:17–24.
5. Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18 (2): 123–33.
6. Ngan RKC. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. Ann Transl Med 2018; 6 (14): 284. DOI: 10.21037/atm.2018.06.11
7. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw 2018;16 (5S): 605–10. DOI: 10.6004/jnccn.2018.0043
8. Hayashida T, Jinno H, Mori K et al. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial. BMC Cancer 2018; 18 (1): 701. DOI: 10.1186/s12885-018-4628-7
9. Iizumi S, Shimomura A, Shimoi T et al. Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. Cancer Chemother Pharmacol 2018. DOI: 10.1007/s00280-018-3617-5
10. Montagna E, Bagnardi V, Cancello G et al. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel) 2018; 13 (3): 177–81. DOI: 10.1159/000487630
11. Egger SJ, Willson ML, Morgan J. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017; 23 (6): CD003374. DOI: 10.1002/14651858.CD003374.pub4
12. Stein J, Mann J. Specialty pharmacy services for patients receiving oral medications for solid tumors. Am J Health Syst Pharm 2016; 73 (11): 775–96. DOI: 10.2146/ajhp150863
13. Poddubnaia I.V., Koliadina I.V. Effektivnaia terapiia raka molochn oi zhelezy preparatami dlia peroral'nogo priema. Journal of Modern Oncology. 2009. 11 (3): 36–8. [in Russian]
14. Li YS, Yang Q, Qi M et al. Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study. Mol Clin Oncol 2017; 7 (4): 661–6. DOI: 10.3892/mco.2017.1351
15. Poddubnaya I.V., Koliadyna I.V., Makarenko N.P. Sbornik klinicheskikh sluchaev dlitel'nogo primeneniia preparata kseloda. Pod red. I.V.Poddubnoi. M., 2012. [in Russian]
16. Kolyadina I.V., Poddubnaya I.V. Kapetsitabin v ad"iuvantnoi terapii raka molochnoi zhelezy. Journal of Modern Oncology. 2010; 12 (3): 23–7. [in Russian]
17. Instruktsiia po preparatu Kapetsitabin. https://www.rlsnet.ru/mnn_index_id_2696.htm [in Russian]
18. Hong JY, Park YH, Choi MK. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clin Breast Cancer 2015; 15 (5): e287–92. DOI: 10.1016/j.clbc.2015.04.004
19. Gilabert M, Bertucci F, Esterni B et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res 2011; 31 (3): 1079–86.
20. Park IH, Im SA, Jung KH et al. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Res Treat 2018. DOI: 10.4143/crt.2017.562. Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
21. Babacan T et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori 2015; 101 (4): 418–23.
22. McBride A, Butler SK. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. Am J Health Syst Pharm 2012; 69 (9): 745–55. DOI: 10.2146/ajhp110237
23. Aseyev O, Ribeiro JM, Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 2016; 17 (4): 589–600. DOI: 10.1517/14656566.2016. 1146683
24. O'Shaughnessy J, McIntyre K, Schwartzberg L et al. Impact of prior antОРacycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. Springerplus 2015; 4: 532. DOI: 10.1186/s40064-015-1322-y
25. Elektronnyi resurs. http://clincancerres.aacrjournals.org/content/17/21/6615 [in Russian]
26. Pivot X. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27 (8): 1525–31. DOI:10.1093/annonc/mdw203
27. Pivot X, Im SA, Guo M et al. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018; 25 (3): 370–4. DOI: 10.1007/s12282-017-0826-4
2. Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная онкология. 2014; 16 (4): 10–20. / Kolyadina I.V., Poddubnaya I.V. Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials). Journal of Modern Oncology. 2014; 16 (4): 10–20. [in Russian]
3. Jacquet E, Lardy-Cléaud A, Pistilli B et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 2018; 95: 93–101. DOI: 10.1016/j.ejca.2018.03.013
4. Gobbini E, Ezzalfani M, Dieras V et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 2018; 96:17–24.
5. Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18 (2): 123–33.
6. Ngan RKC. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. Ann Transl Med 2018; 6 (14): 284. DOI: 10.21037/atm.2018.06.11
7. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw 2018;16 (5S): 605–10. DOI: 10.6004/jnccn.2018.0043
8. Hayashida T, Jinno H, Mori K et al. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial. BMC Cancer 2018; 18 (1): 701. DOI: 10.1186/s12885-018-4628-7
9. Iizumi S, Shimomura A, Shimoi T et al. Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. Cancer Chemother Pharmacol 2018. DOI: 10.1007/s00280-018-3617-5
10. Montagna E, Bagnardi V, Cancello G et al. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel) 2018; 13 (3): 177–81. DOI: 10.1159/000487630
11. Egger SJ, Willson ML, Morgan J. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017; 23 (6): CD003374. DOI: 10.1002/14651858.CD003374.pub4
12. Stein J, Mann J. Specialty pharmacy services for patients receiving oral medications for solid tumors. Am J Health Syst Pharm 2016; 73 (11): 775–96. DOI: 10.2146/ajhp150863
13. Поддубная И.В., Колядина И.В. Эффективная терапия рака молочной железы препаратами для перорального приема. Современная онкология. 2009. 11 (3): 36–8. / Poddubnaia I.V., Koliadina I.V. Effektivnaia terapiia raka molochn oi zhelezy preparatami dlia peroral'nogo priema. Journal of Modern Oncology. 2009. 11 (3): 36–8. [in Russian]
14. Li YS, Yang Q, Qi M et al. Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study. Mol Clin Oncol 2017; 7 (4): 661–6. DOI: 10.3892/mco.2017.1351
15. Поддубная И.В., Колядина И.В., Макаренко Н.П. Сборник клинических случаев длительного применения препарата кселода. Под ред. И.В.Поддубной. М., 2012. / Poddubnaya I.V., Koliadyna I.V., Makarenko N.P. Sbornik klinicheskikh sluchaev dlitel'nogo primeneniia preparata kseloda. Pod red. I.V.Poddubnoi. M., 2012. [in Russian]
16. Колядина И.В., Поддубная И.В. Капецитабин в адъювантной терапии рака молочной железы. Современная онкология. 2010; 12 (3): 23–7. / Kolyadina I.V., Poddubnaya I.V. Kapetsitabin v ad"iuvantnoi terapii raka molochnoi zhelezy. Journal of Modern Oncology. 2010; 12 (3): 23–7. [in Russian]
17. Инструкция по препарату Капецитабин. https: //www. rlsnet.ru/mnn_index_id_2696.htm / Instruktsiia po preparatu Kapetsitabin. https://www.rlsnet.ru/mnn_index_id_2696.htm [in Russian]
18. Hong JY, Park YH, Choi MK. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clin Breast Cancer 2015; 15 (5): e287–92. DOI: 10.1016/j.clbc.2015.04.004
19. Gilabert M, Bertucci F, Esterni B et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res 2011; 31 (3): 1079–86.
20. Park IH, Im SA, Jung KH et al. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Res Treat 2018. DOI: 10.4143/crt.2017.562. Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
21. Babacan T et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori 2015; 101 (4): 418–23.
22. McBride A, Butler SK. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. Am J Health Syst Pharm 2012; 69 (9): 745–55. DOI: 10.2146/ajhp110237
23. Aseyev O, Ribeiro JM, Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 2016; 17 (4): 589–600. DOI: 10.1517/14656566.2016. 1146683
24. O'Shaughnessy J, McIntyre K, Schwartzberg L et al. Impact of prior antОРacycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. Springerplus 2015; 4: 532. DOI: 10.1186/s40064-015-1322-y
25. Электронный ресурс. http://clincancerres.aacrjournals.org/content/17/21/6615 / Elektronnyi resurs. http://clincancerres.aacrjournals.org/content/17/21/6615 [in Russian]
26. Pivot X. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27 (8): 1525–31. DOI:10.1093/annonc/mdw203
27. Pivot X, Im SA, Guo M et al. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018; 25 (3): 370–4. DOI: 10.1007/s12282-017-0826-4
________________________________________________
2. Kolyadina I.V., Poddubnaya I.V. Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials). Journal of Modern Oncology. 2014; 16 (4): 10–20. [in Russian]
3. Jacquet E, Lardy-Cléaud A, Pistilli B et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 2018; 95: 93–101. DOI: 10.1016/j.ejca.2018.03.013
4. Gobbini E, Ezzalfani M, Dieras V et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 2018; 96:17–24.
5. Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18 (2): 123–33.
6. Ngan RKC. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. Ann Transl Med 2018; 6 (14): 284. DOI: 10.21037/atm.2018.06.11
7. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw 2018;16 (5S): 605–10. DOI: 10.6004/jnccn.2018.0043
8. Hayashida T, Jinno H, Mori K et al. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial. BMC Cancer 2018; 18 (1): 701. DOI: 10.1186/s12885-018-4628-7
9. Iizumi S, Shimomura A, Shimoi T et al. Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. Cancer Chemother Pharmacol 2018. DOI: 10.1007/s00280-018-3617-5
10. Montagna E, Bagnardi V, Cancello G et al. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel) 2018; 13 (3): 177–81. DOI: 10.1159/000487630
11. Egger SJ, Willson ML, Morgan J. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017; 23 (6): CD003374. DOI: 10.1002/14651858.CD003374.pub4
12. Stein J, Mann J. Specialty pharmacy services for patients receiving oral medications for solid tumors. Am J Health Syst Pharm 2016; 73 (11): 775–96. DOI: 10.2146/ajhp150863
13. Poddubnaia I.V., Koliadina I.V. Effektivnaia terapiia raka molochn oi zhelezy preparatami dlia peroral'nogo priema. Journal of Modern Oncology. 2009. 11 (3): 36–8. [in Russian]
14. Li YS, Yang Q, Qi M et al. Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study. Mol Clin Oncol 2017; 7 (4): 661–6. DOI: 10.3892/mco.2017.1351
15. Poddubnaya I.V., Koliadyna I.V., Makarenko N.P. Sbornik klinicheskikh sluchaev dlitel'nogo primeneniia preparata kseloda. Pod red. I.V.Poddubnoi. M., 2012. [in Russian]
16. Kolyadina I.V., Poddubnaya I.V. Kapetsitabin v ad"iuvantnoi terapii raka molochnoi zhelezy. Journal of Modern Oncology. 2010; 12 (3): 23–7. [in Russian]
17. Instruktsiia po preparatu Kapetsitabin. https://www.rlsnet.ru/mnn_index_id_2696.htm [in Russian]
18. Hong JY, Park YH, Choi MK. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clin Breast Cancer 2015; 15 (5): e287–92. DOI: 10.1016/j.clbc.2015.04.004
19. Gilabert M, Bertucci F, Esterni B et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res 2011; 31 (3): 1079–86.
20. Park IH, Im SA, Jung KH et al. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Res Treat 2018. DOI: 10.4143/crt.2017.562. Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
21. Babacan T et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori 2015; 101 (4): 418–23.
22. McBride A, Butler SK. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. Am J Health Syst Pharm 2012; 69 (9): 745–55. DOI: 10.2146/ajhp110237
23. Aseyev O, Ribeiro JM, Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 2016; 17 (4): 589–600. DOI: 10.1517/14656566.2016. 1146683
24. O'Shaughnessy J, McIntyre K, Schwartzberg L et al. Impact of prior antОРacycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. Springerplus 2015; 4: 532. DOI: 10.1186/s40064-015-1322-y
25. Elektronnyi resurs. http://clincancerres.aacrjournals.org/content/17/21/6615 [in Russian]
26. Pivot X. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27 (8): 1525–31. DOI:10.1093/annonc/mdw203
27. Pivot X, Im SA, Guo M et al. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018; 25 (3): 370–4. DOI: 10.1007/s12282-017-0826-4
Авторы
И.В.Колядина*1,2, И.В.Поддубная1
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*irinakolyadina@yandex.ru
1 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
2 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*irinakolyadina@yandex.ru
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*irinakolyadina@yandex.ru
________________________________________________
1 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
2 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*irinakolyadina@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.